trial

M1 Schizophrenia PET Study

NCTId NCT05105542
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 18 (actual)
Sponsored by Yale University
Primary completion 2023-10-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
18 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2021-04-20
Primary completion
2023-10-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
11C-EMO - A Novel PET Radiotracer for Muscarinic M1 ReceptorPET Scan

Sponsors

Yale UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Rajiv Radhakrishnan, MDPrincipal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
18
Phase
PHASE1
Primary Completion Date
2023-10-31
Status
COMPLETED
relationships
The graph out of here
drug
11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor
drug
PET Scan
drug
lead_sponsor
Yale University
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizoaffective Disorder
indication
Healthy
indication
Psychotic Disorders
indication
investigator
Rajiv Radhakrishnan, MD
person